Hetero收到的通用Sofosbuvir(Gilead Sovaldi)印度药品管理总批准

StephenW

Hetero Received Generic Sofosbuvir (Gilead's Sovaldi) Approval From Drug Controller General of India (DCGI)

HYDERABAD, INDIA--(Marketwired - Mar 12, 2015) - Hetero, a leading pharmaceutical company based in Hyderabad, India, today announced that it has received approval for generic Sofosbuvir Tablets, 400 mg, from Drug Controller General of India.

Hetero will launch Sofosbuvir under its brand Sofovir in India. Hetero will price its generic medicine at Rs 19,900/- for a bottle of 28 tablets and will launch the medicine this month in India and other countries soon. Hetero has also tied up with various other Licensee holders to distribute the generic Sofosbuvir in India.

Sofosbuvir 400 mg tablets, a once-daily oral dose, is being used for the treatment of chronic hepatitis C infection across the world. This will herald the beginning of a new era in Hepatitis-C treatment.

Hetero has a non-exclusive License Agreement with Gilead Sciences, Ireland to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.

"Hepatitis C is a growing public health concern, particularly in developing countries such as India, and Hetero is committed to bringing affordable Sofosbovir to India," said Vamsi Krishna, Director-Hetero.

About Hetero

Hetero is a leading global pharmaceutical company and provides Custom Pharmaceutical Services. Founded in 1993, Hetero maintains 20 facilities across the globe and markets a portfolio of over 200 products in 138 countries. Hetero's commitment to reliability, quality, capacity, and value have been a cornerstone since its inception, and the company offers a unique value proposition in its ability to create efficiencies through vertical integration of contract manufacturing services.

杂接收到的通用Sofosbuvir（Gilead公司Sovaldi）批准印度药品管理总局（DCGI）

印度海德拉巴 - （Marketwired  -  2015年3月12日） - 杂，总部设在印度海得拉巴一家领先的制药公司今天宣布，它已经获得了通用Sofosbuvir片，400毫克，印度药品管理总局。

异质将推出Sofosbuvir其品牌Sofovir在印度下。异质价格将其仿制药卢比19900 /  - 一瓶28粒，将在印度和其他国家尽快在本月推出了药。杂也追平了其他各种许可持有人分配通用Sofosbuvir在印度。

Sofosbuvir 400毫克片剂，每日一次口服剂量，正被用于治疗慢性丙型肝炎感染在世界各地的治疗。这将预示着在丙型肝炎治疗的新时代的开始。

异质与Gilead Sciences公司，爱尔兰的非独家许可协议，以生产和在91发展中国家出售其慢性丙型肝炎药物的仿制药。

“丙型肝炎是一个日益严重的公共健康问题，特别是在发展中国家，如印度和杂致力于将经济实惠Sofosbovir印度，”Vamsi克里希纳，主任杂说。

关于异质

异质是全球领先的制药公司，并提供定制医药服务。成立于1993年，杂保持在全球20家工厂和销售超过200种产品在138个国家的投资组合。杂承诺的可靠性，质量，容量和价值已自成立以来的基石，企业提供独特的价值主张在其通过合同生产服务的垂直整合创造效益的能力。